Drug Screening Services

Protheragen delivers tailored drug screening services for rare neurodegenerative disorders, focusing on tackling the unique challenges posed by these complex conditions. By combining cutting-edge tools with scientific know-how, we aim to speed up the hunt for treatments while offering dependable testing systems that balance accuracy and real-world relevance.

Why Drug Screening Matters in Rare Neurodegenerative Diseases

Drug screening is key to finding therapies for rare neurodegenerative diseases, which involve progressive nerve cell loss and worsening symptoms. Standard methods often fall short due to the rarity and intricate biology of these disorders. To bridge this gap, researchers now rely on advanced methods like high-throughput screening (HTS) and patient-derived models to efficiently spot promising candidates.

Drug Screening Workflow

Target Identification. Molecular targets linked to disease mechanisms are identified through genetic profiling and multi-omics analyses.
High-Throughput Screening. Automated platforms screen large compound libraries to identify molecules that modulate target activity, expediting early-stage discovery.
Lead Optimization. Hit compounds are refined to enhance efficacy, selectivity, and pharmacokinetics using computational modeling and medicinal chemistry.
Preclinical Validation. Candidates undergo rigorous testing in disease-specific models, including patient-derived cell assays and genetically engineered animals, to evaluate therapeutic potential and safety.
Biomarker-Driven Analysis. Biomarkers are incorporated to monitor treatment response and disease progression, enabling precision in candidate selection.

Impact on Neurodegenerative Research

Drug screening not only accelerates therapeutic discovery but also clarifies disease pathways. Patient-derived iPSC models, for example, enhance screening accuracy by replicating human-specific pathology, bridging gaps between preclinical data and clinical outcomes. This integrated approach supports the identification of novel targets and the development of tailored therapies for heterogeneous patient populations.

Fig1. Strategies for integrative modeling of human disease pathophysiology and drug discovery using patient-specific iPSC models. (Haggarty, et al., 2016)

Our Services

Protheragen supports rare neurodegenerative disease research with comprehensive drug screening services. Our offerings cover high-throughput screening, lead compound optimization, and preclinical testing, addressing the unique challenges of these complex conditions. Combining advanced technologies with specialized expertise, we help researchers advance candidates from early discovery to clinical development with confidence.

Key Services

High-Throughput Screening (HTS)

We screen large compound libraries to identify potential therapeutic candidates. Our platforms prioritize sensitivity and specificity, ensuring reliable detection of molecules with disease-modifying activity.

Lead Compound Optimization

Through structure-activity relationship (SAR) analysis and pharmacokinetic (PK) studies, we refine lead compounds to enhance efficacy, selectivity, and safety. Customized strategies ensure candidates perform consistently across experimental models.

Preclinical Efficacy and Safety Testing

We validate candidates using disease-relevant cell assays and animal models. Testing includes dose-response evaluations, toxicity profiling, and mechanistic studies to confirm safety and therapeutic potential before clinical trials.

Additional Services

We provide pharmacokinetic (ADME) and toxicology assessments to evaluate drug metabolism and safety. Custom screening workflows—such as target-specific assays or biomarker-integrated approaches—are available to meet specialized research needs. Our services adapt to projects at any stage, ensuring alignment with both exploratory and translational goals.

Protheragen specializes in drug screening solutions for rare neurodegenerative diseases, offering HTS, lead optimization, and preclinical validation. Our technologies and expertise help bridge the gap between discovery and clinical translation. To learn more or request a quote, contact our team to discuss your project needs.

Why Choose Us?

Advanced Tools: We use the latest high-speed screening tech and precise analysis tools to get you reliable, repeatable results every time.
Skilled Team: Our team has years of real-world experience. We don't just follow scripts—we adapt solutions to fit your project's unique hurdles.
Full-Cycle Help: Whether you're starting with early drug discovery or gearing up for preclinical tests, we've got your back at every step to avoid delays.
No Guesswork: We run tight quality checks and keep you in the loop with clear updates, tweaking our approach as your needs evolve.

FAQs

Q: What kinds of compounds can you test? A: We handle everything—small molecules, peptides, biologics—to hunt down promising treatments for tough neurodegenerative diseases.
Q: How long will the screening take? A: Most projects wrap up in 4–8 weeks, but it depends on your compound list size and how tricky your assays are.
Q: What technologies do you use for screening? A: Our screening combines automated liquid handling, high-content imaging, and other advanced HTS platforms to ensure accuracy and scalability.
Q: Can you provide custom screening services? A: Yes. We design tailored workflows—from compound library screening to lead optimization—to align with your project's unique goals and experimental parameters.

Reference

Haggarty SJ.; et al. Advancing drug discovery for neuropsychiatric disorders using patient-specific stem cell models. Mol Cell Neurosci. 2016;73:104-115.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Related Disease Solutions